학술논문
Evaluation of anti‐factor VIII antibodies in haemophilia A subjects switching products following a provincial tender.
Document Type
Article
Author
Source
Subject
*BLOOD coagulation factor VIII antibodies
*HEMOPHILIA
*VON Willebrand disease
*BLOOD coagulation factor VIII
*CHILD patients
*HEMOPHILIACS
*NEUTRALIZATION tests
*
*
*
*
*
*
Language
ISSN
1351-8216
Abstract
Evaluation of anti-factor VIII antibodies in haemophilia A subjects switching products following a provincial tender Haemophilia A, inhibitor, recombinant factor VIII, bleeds, factor VIII usage, switching products Keywords: bleeds; factor VIII usage; haemophilia A; inhibitor; recombinant factor VIII; switching products EN bleeds factor VIII usage haemophilia A inhibitor recombinant factor VIII switching products e1 e4 4 01/13/22 20220101 NES 220101 In 2018, following a provincial tender process, most persons with haemophilia A (PWHA) in the province of Quebec (Canada) were switched to the two recombinant B-domain-truncated factor VIII (FVIII) known as Zonovate® (NovoNordisk, Mississauga, Canada) and Nuwiq® (Octapharma AG, Lachen, Switzerland) with an estimated market distribution of respectively 53% and 47%. [Extracted from the article]